$21.50
1.035.03%
Últ. Act.: Oct 20, 5:00 PM
$21.50
1.035.03%
NewAmsterdam Pharma Co (NAMS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.43 | $-0.43 | $-0.38 | $-0.36 |
| Actual | $-0.52 | $-0.40 | $-0.63 | $-0.61 |
| Surprise | -20.9% | +6.98% | -65.8% | -69.4% |
| Revenue | ||||
| Estimate | $2.4M | $1.2M | $4.3M | $4.3M |
| Actual | $3.7M | $3.0M | $32000 | $348000 |
| Surprise | +53.2% | +155.4% | -99.3% | -91.9% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.45 | $-0.39 | $-0.57 | $-0.61 |
| Revenue | ||||
| Consensus | $7.4M | $16.4M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $-0.52 | $-0.43 | -20.9 % |
| Q1 | May 7, 2026 | $-0.40 | $-0.43 | 6.98 % |
| Q4 | Feb 18, 2026 | $-0.63 | $-0.38 | -65.8 % |
| Q3 | Nov 5, 2025 | $-0.61 | $-0.36 | -69.4 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $3.70M | $2.42M | 53.2 % |
| Q1 | May 7, 2026 | $3.04M | $1.19M | 155.4 % |
| Q4 | Feb 18, 2026 | $32.00K | $4.33M | -99.3 % |
| Q3 | Nov 5, 2025 | $348.00K | $4.29M | -91.9 % |